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Abstract
Hypertension is an important independent risk factor for renal disease. If hypertension and chronic renal disease
co-exist, as is common in patients with diabetes mellitus, the risk of cardiovascular disease is heightened. The
importance of rigorous blood pressure control is recognized in current guidelines, with a recommended target of
office blood pressure of < 130/80 mmHg; although ambulatory blood pressure may be more appropriate in order
to identify the 24-hour hypertensive burden. Even lower blood pressure may further reduce the progression of
chronic kidney disease, but the incidence of cardiovascular events may increase. Albuminuria not only indicates
renal damage, but is also a powerful predictor of cardiovascular morbidity and mortality at least in patients with
high cardiovascular risk and potentially pre-existing vascular damage. Management of the multiple factors for renal
and cardiovascular disease is mandatory in the diabetic patient. The renin-angiotensin system (RAS) plays a pivotal
role in the progression of renal disease, as well as in hypertension and target-organ damage. The use of agents
that target the RAS confer renoprotection in addition to antihypertensive activity. There is extensive evidence of
the renoprotective effect of angiotensin II receptor blockers (ARBs), and specifically telmisartan. In addition to pro-
viding 24-hour blood pressure control, clinical studies in patients with diabetes show that telmisartan improves
renal endothelial function, prevents progression from microalbuminuria to macroalbuminuria, slows the decline in
glomerular filtration rate and reduces proteinuria in overt nephropathy. These effects cannot be solely attributed to
blood pressure control. In contrast to other members of the ARB class, the renoprotective effect of telmisartan is
not confined to the management of diabetic nephropathy; slowing the progression of albuminuria has been
demonstrated in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTAR-
GET®), which included diabetic and non-diabetic patients at high risk of cardiovascular events.
Introduction - the ONTARGET® study
The ONgoing Telmisartan Alone and in combination
with Ramipril Global Endpoint Trial (ONTARGET®)
was the largest ever study of an angiotensin II receptor
blocker (ARB) [1]. It compared telmisartan with rami-
pril, and the combination, with a treatment duration of
up to 5.5 years. ONTARGET® was notable not only for
the size of the patient population (over 25,000), but also
for the broad inclusion criteria (patients could have cor-
onary artery disease, peripheral arterial occlusive disease,
cerebrovascular event or diabetes mellitus with end-
organ damage). Patients were screened for tolerance to
angiotensin-converting enzyme (ACE) inhibitors before
trial entry.
ONTARGET® showed that telmisartan was as effective
as ramipril, the ACE inhibitor whose efficacy in reducing
cardiovascular events was established in the Heart Out-
comes Prevention Evaluation (HOPE) study [2] and that
has since become a widely used intervention for cardiovas-
cular protection. Telmisartan was better tolerated than
ramipril, despite intolerance of an ACE inhibitor being
screened for in the study run-in period. The parallel trial,
Telmisartan Randomized AssessmeNt Study in aCE iNtol-
erant Subjects with Cardiovascular Disease (TRANS-
CEND®), in nearly 6,000 patients intolerant of ACE
inhibitors, showed that telmisartan significantly reduced
the cardiovascular composite of cardiovascular death,
myocardial infarction and stroke (although not heart fail-
ure) compared with placebo, when administered on a
background of otherwise optimal standard of care [3].
The ONTARGET® trial established telmisartan as a
proven option for the prevention of cardiovascular
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inhibitors are currently used to slow the onset and pro-
gression of diabetic nephropathy. Recent analyses of the
ONTARGET® trial have provided evidence for slowing
the progression of renal disease demonstrated by level
of microalbuminuria in at-risk patients, including those
with diabetes, being treated with telmisartan or ramipril
[4,5]. These data are of particular interest given the link
between renal and cardiovascular disease.
In this review, we place these results in the context of
existing data on telmisartan in diabetic nephropathy,
beginning with a review of renal and cardiovascular
disease.
Assessing the magnitude of renal impairment
Serum creatinine, a commonly used indicator of renal
impairment, shows substantial inter-individual variability
due to non-renal factors - mainly due to differences in
muscle mass. To quantify accurately the degree of dys-
function, measured levels must be adjusted for the
effects of age and gender; for example, to provide an
estimated glomerular filtration rate (GFR). The equation
developed for use in the Modification of Diet in Renal
Disease (MDRD) study [6] is now widely used to mea-
sure renal function, although it is only valid for an esti-
mated GFR < 60 mL/min (the conventional threshold
for chronic kidney disease) [7]. To address the limita-
tions of the MDRD equation, the Chronic Kidney Dis-
ease Epidemiology Collaboration equation has been
d e v e l o p e dt h a tp e r f o r m sb e t t e ra th i g h e rG F R s[ 8 ] .
Cystatin C levels provide a more accurate measure of
early stages of renal impairment, but this approach is
currently not widely adopted [9].
The simplest and most widespread tool for identifying
early changes in renal function is the dipstick test for
albumin in early morning urine [10]. Normo-albumi-
nuria is conventionally defined as levels < 30 mg/24
hours, microalbuminuria as 30-299 mg/24 hours, and
macroalbuminuria as ≥ 300 mg/24 hours. Alternatively,
albuminuria may be expressed as a urinary albumin/
creatinine ratio (UACR), macroalbuminuria being ≥ 300
mg/g creatinine [11]. A new definition of total protei-
nuria and albuminuria has been agreed upon and
demonstrated effective (Table 1) [12]. This addresses the
fallacies associated with the use of the terms “microal-
buminuria” and “macroalbuminuria” as being distinct
entities. In reality, there is a continuous relationship
between albuminuria and cardiovascular and renal out-
come, and even low-level albuminuria is associated with
increased cardiovascular morbidity and mortality.
Although albuminuria is extensively used to identify
renal impairment in patients with diabetes, it is possible
to have a low estimated GFR (< 60 mL/min/1.73 m
2)
despite normoalbuminuria [13]. Such individuals, who
are typically older, female, hypertensive and have cardio-
vascular disease, are as likely to experience a cardiovas-
cular event as people with microalbuminuria and an
estimated GFR >60 mL/min/1.73 m
2. Both parameters
should be employed to identify accurately all patients at
increased risk of cardiovascular disease.
The link between chronic kidney disease and
cardiovascular disease
Chronic kidney disease is a continuum of pathology that
manifests as decreased glomerular filtration and
increased albuminuria. Albuminuria is an important, but
somewhat overlooked, risk factor. Even small increases
in albuminuria elevate the risk of end-stage renal disease
(ESRD) [14], and the presence of albuminuria may be
used to refine estimates of the risk of developing ESRD
and cardiovascular disease compared with estimated
GFR alone [15]. Once abnormal levels of albumin are
detected in the urine of patients with diabetes, death
from cardiovascular disease is more likely than the
development of renal failure [16], although a substantial
proportion of patients will still develop ESRD. A 5-year
prospective study of 27,998 patients with renal impair-
ment, of whom 15.8% were identified as having diabetes
as the primary cause of renal disease, found that the
incidence of death was 19.5% and that of renal replace-
ment therapy was only 1.1% in the patients who started
the study with stage 2 chronic kidney disease (estimated
GFR 60-89 mL/min/1.73 m
2) [17]. For patients with
stage 3 disease (estimated GFR 30-59 mL/min/1.73 m
2),
the respective incidences were 24.3% and 1.3%. In those
with stage 4 disease (estimated GFR 15-29 mL/min/1.73
m
2), the incidence rose to 45.7% and 19.9%, respectively.
The presence of diabetes at baseline resulted in a higher
incidence of death for each stage of chronic kidney dis-
ease, and the relatively high incidence of death in the
stage 2 cohort was attributed to patients with diabetes.
Patients with diabetic nephropathy account for 27% of
those undergoing dialysis [18]. Once a patient is on dia-
lysis, the risk of dying of cardiovascular disease in an
individual under 30 years old is equivalent to adding
50 years to his or her actual age [19].
Post-hoc analysis of data from the HOPE trial showed
that, in addition to diabetes being associated with
increased risk of renal impairment, microalbuminuria
was associated with an increa s ei nt h ep r i m a r yc a r d i o -
vascular endpoint. However, in the presence of renal
impairment, the likelihood of a major cardiovascular
event was similar in diabetic and non-diabetic patients;
in the overall patient population, the odds ratio of 1.6
for microalbuminuria was similar to that of 1.5 for cor-
onary artery disease [20] The Action in Diabetes and
Vascular disease: PreterAx and DiamicroN-MR
Controlled Evaluation (ADVANCE) showed that the
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with the reduction in a renal event [21]. Similarly, in the
patients with hypertension and left-ventricular hypertro-
phy studied in the Losartan Intervention For Endpoint
r e d u c t i o ni nh y p e r t e n s i o n( L I F E )t r i a l ,U A C R sd i r e c t l y
correlated with the incidence of cardiovascular morbid-
ity and mortality [22]. In the 1,063 diabetic patients in
LIFE, a 10-fold increase in UACR increased the hazard
ratio (HR) for the composite endpoint of cardiovascular
or all-cause mortality, stroke or myocardial infarction by
39.6% and cardiovascular mortality by 46.9%. Even in
patients whose values were within the normoalbuminu-
ric range, cardiovascular risk increased according to
urinary albumin levels.
Evaluating risk in patients with renal impairment
Risk can be expressed as in absolute, individual or life-
time terms. Absolute risk is derived from epidemiologi-
cal studies in large patient populations. Risk calculators
provide an overall measure of the survival in the average
person within a given population, and are frequently
extrapolated to the general population [23]. These data
are used by governments and other healthcare providers,
together with evidence of the impact of specific inter-
ventions gathered from outcome trials, to determine the
most cost-effective means of maintaining a large healthy
population and treating those who are sick. The deci-
sions made largely take into account the age distribution
of the population; other considerations are clinical sta-
tus, ethnicity and psychosocial and socioeconomic fac-
tors. However, patients at risk of cardiovascular disease
have an aggregate of risk factors present at varying
degrees of severity.
Individual risk estimates are based on the presence of
specific modifiable and non-modifiable risk factors.
Metabolic syndrome, for example, can result from the
presence of various combinations of modifiable risk fac-
tors, each having an effect on the overall risk [24]. How-
ever, the use of risk calculators for patients with clearly
identifiable evidence of vascular disease, such as diabetes
with retinopathy or peripheral arterial obstructive dis-
ease, serves no purpose, since the need for treatment is
self-evident. Another disadvantage of risk calculators is
that they do not take into account early pathological
changes, such as vascular calcification. Estimation of
risk does not in itself provide a shortcut for therapeutic
decision making. Outcomes trials can only demonstrate
the benefits of treatment in a clearly defined patient
population. Very high-risk patients, for example, are
often excluded from clinical trials, but these are the very
patients that need aggressive management. Results of
subgroup analyses of large-scale trials may provide
further insight into responses to treatment in patients
w i t has p e c i f i cd e g r e eo fd isease severity within the
overall entry requirements. As a result, in selecting
treatment for individual patients, physicians should be
guided by the findings of outcome trials, but should be
prepared to interpret the results for the specific patient
under consideration.
Lifetime risk, the third of the risk formulations, gives
guidance on the optimal stage for intervention. Although
the data are limited, they suggest that life-long exposure
to specific risk factors can drastically shorten life expec-
tancy. Early management of these risk factors by personal
and country-wide interventions can improve prognosis
and extend the number of healthy life-years [25].
Diabetic nephropathy - incidence and risk factors
Nephropathy is particularly prevalent in the diabetic
patient. Based on a threshold of estimated GFR < 60 mL/
min/1.73 m
2, the prevalence among adults in the general
population is 4.6% in the United States and Europe [26].
By comparison, the incidence of nephropathy in people
with diabetes is 26.4%. The UK Prospective Diabetes
Study (UKPDS) found high rates of renal-disease progres-
sion in type 2 diabetes, with an annual rate of transition
from normoalbuminuria to microalbuminuria of 2%, from
microalbuminunria to macroalbuminuria of 2.8%, and
from macroalbuminuria with normal serum creatinine to
serum creatinine levels >175 μmol/L of 2.3% [16]. The
incidence of death increases as chronic kidney disease pro-
gresses, and the 20-year survival rate of a patient with type
2 diabetes and nephropathy is only about 50% [16].
Several pathological mechanisms link diabetes with the
progression of renal disease. In the early stages of
nephropathy in individuals with diabetes, a number of
Table 1 New definitions of total proteinuria and albuminuria [12]
Assay Normal Low High (previously termed
microalbuminuria)







Spot UACR (mg/g)* < 10 10-
29
30-300 (males,17-250; females,25-355) >300 (males, >250; females >355)
UACR, urinary albumin/creatine ratio.
Correspondence among terms is inexact; therefore, threshold levels are not consistent.
*For conversion of UACR expressed as mg/mmol, multiply by 0.113.
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lar membrane that lead to increased permeability to
proteins. Among those identified are damage to the
podocytes, changes in the expression of matrix proteins,
loss of selectivity and charge, as well as damage to the
endothelium with consequent endothelial dysfunction
[27-30]. Angiotensin II-mediated haemodynamic
mechanisms increase the intra-glomerular pressure and
result in the excretion of proteins [31].
The risk for diabetic nephropathy is multi-factorial
and includes a family history of diabetes [32] and life-
style factors, with a resultant high body mass index [33].
One of the more intriguing risk factors appears to be a
low birth weight [34-36]. Intra-uterine programming
and loss of nephrons may render the kidneys of an indi-
vidual with low birth weight more susceptible to hyper-
tension or diabetes [37]. Low birth weight is also
associated with retinal arteriolar narrowing in both chil-
dren and middle-aged adults [38,39].
High blood pressure is well established as an important
risk factor for type 2 diabetes. In the Atherosclerosis Risk
in Communities (ARIC) study, individuals with systolic
blood pressure (SBP)/diastolic blood pressure (DBP) >140/
90 mmHg were 2.5 times more likely to develop diabetes
than their normotensive counterparts [40]. Also, high
blood pressure is a strong predictor of ESRD, and the risk
is amplified if blood pressure is high in patients who sub-
sequently develop diabetes [41]. The possibility that hyper-
glycaemia appears to sensitize the kidneys to the harmful
effect of hypertension was first mooted in 1969 [42]. In a
normotensive rat model, at least, progressive proteinuria
only occurs when deoxycorticosterone acetate-induced
hypertension is superimposed on hyperglycemia [43].
Effect of blood pressure control on chronic kidney
disease
In people without diabetes, the benefits of lowering blood
pressure on chronic kidney disease are not conclusive.
The MDRD study showed that, with intensive blood
pressure control that resulted in a mean arterial pressure
of 91 mmHg, the decline in estimated GFR was 1.9 mL/
min/year [44]. By comparison, with ordinary blood pres-
sure control (mean arterial pressure 107 mmHg) the rate
of loss was 3.4 mL/min/year. However, the difference
between the two approaches to treatment was not statis-
tically significant [44]. A 10-year follow-up, however,
found that there was a 32% reduction in renal failure in
patients with a mean arterial pressure of < 92 mmHg in
comparison with those in whom normal blood pressure
control was achieved [45].
The evidence is more conclusive for patients with type
2 diabetes. Over a 5-year follow-up, intensive control
(mean SBP/DBP 128/75 mmHg) slowed the progression
from normoalbuminuria to microalbuminuria, and from
microalbuminuria to macroalbuminuria, compared with
conventional control, which resulted in mean SBP/DBP
of 137/81 mmHg (Figure 1) [46]. The benefit of vigor-
ous blood pressure control in patients with diabetes is
supported by recently reported findings from the
ADVANCE trial: renal events were least frequent if SBP
was < 110 mmHg and increased log-linearly with
increasing SBP [47]. Although the Irbesartan in Diabetic
Nephropathy Trial (IDNT) also observed that the inci-
dence of a renal endpoint gradually fell with the pro-
gressive lowering of SBP to < 121 mmHg after 1 year, a
similar reduction in mortality was apparent only to an
SBP of 121-130 mmHg, and an SBP < 121 mmHg was
associated with a three-fold increase in all-cause mortal-
ity [48]. The increase in mortality may be explained by
the difference in the patient populations studied:
patients in IDNT were at higher cardiovascular risk
because of established diabetic nephropathy and 29%
had a history of cardiovascular disease [49]. However,
the lower the better may not be true, as shown in the
Action to Control CardiOvascular Risk in Diabetes
(ACCORD) trial, in which patients with type 2 diabetes
at high cardiovascular risk did not benefit from SBP
lowering below 120 mmHg [50].
These findings are reflected in the lower blood pres-
sure targets for patients with diabetes. The European
Society of Hypertension/European Society of Cardiology
(ESH/ESC) guidelines recognize that the target blood
pressure depends on the presence of additional risk
factors for cardiovascular disease and the presence of
target-organ damage [51]. The presence of ≥ 3r i s kf a c -
tors, target-organ damage, or diabetes places a patient at
high risk; thus, the recommendation is that diabetic
patients with SBP/DBP >130/85 mmHg should be trea-
ted [51]. The blood pressure targets recommended in
Figure 1 Kaplan-Meier curve showing progression from
microalbuminuria (30-300 mg/24 hours) to overt albuminuria
(>300 mg/24 hours) in patients with type 2 diabetes during
conventional and intensive blood pressure lowering [46].
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or ambulatory blood pressure measurements provide a
superior indication of blood pressure control [52] and
may better reflect the patient’s risk. One analysis has
f o u n dt h a tu n c o n t r o l l e da w a k ea m b u l a t o r yb l o o dp r e s -
sure (SBP >130 mmHg) increases the risk of micro- or
macroalbuminuria, even if office blood pressure was
controlled [53]. Other observations in children with type
1 diabetes and elderly patients with type 2 diabetes have
shown that elevated night-time blood pressure more
accurately predicts albuminuria than office blood pres-
sure [54,55]. Although association does not prove caus-
ality, use of an antihypertensive agent that provides
24-hour blood pressure control may provide better
renoprotection.
Renin-angiotensin system blockade - effects beyond
blood pressure control
There is substantial evidence that drugs that act on the
renin-angiotensin system (RAS) may have a beneficial
effect on diabetic nephropathy, which is greater than the
effects that would be expected purely from blood pres-
sure reduction. A meta-analysis of recent studies showed
that, compared with other antihypertensive classes with
different mechanisms of action, treatment with ACE
inhibitors or ARBs reduces new-onset diabetes by 22%
in patients with or without hypertension and at high
risk of developing diabetes [56]. In patients with diabetic
nephropathy, for comparable levels of blood pressure
achieved in IDNT using the ARB irbesartan or the cal-
cium channel blocker amlodipine, the relative risk of
developing a renal endpoint was lower with irbesartan
[47]. Similarly, the Reduction of Endpoints in NIDDM
with the Angiotensin II Antagonist Losartan (RENAAL)
trial showed that the renal protection conferred by
losartan exceeded that attributable to the small differ-
ences in blood pressure reduction compared with the
control group, which received standard antihypertensive
therapy, other than an ARB [57] Despite these data, one
should not decry the importance of blood pressure
control.
The most recent data showing the renoprotective effect
of an ARB comes from the Randomized Olmesartan And
Diabetes MicroAlbuminuria Protection (ROADMAP)
trial [58]. This study was conducted in patients with type
2 diabetes and one additional cardiovascular risk factor
(hypercholesterolaemia, low high-density lipoprotein
cholesterol, hypertriglyceridaemia, obesity, large waist
circumference, hypertension and/or a smoker) and who
were normoalbuminuric. After adjustment for blood
pressure differences, olmesartan reduced the reduction of
risk of onset of persistent microalbuminuria (primary
endpoint) by 17% compared with placebo, with only
borderline statistical significance.
There may, however, be a distinction between reno-
protection afforded by RAS blockade in patients with
type 1 and type 2 diabetes based on the findings of
recent studies. An evaluation of the 3,326 with type 1
and the 1,905 with type 2 diabetes, most of whom were
normotensive and all were normoalbuminuric at base-
line, included in the DIabetic REtinopathy Candesartan
Trials (DIRECT) showed that candesartan 32 mg did
not prevent microalbuminuria [59]. Another study con-
ducted exclusively in patients with type 1 diabetes, who
were both normotensive and normalbuminuric on enrol-
ment, found that neither losartan nor enalapril slow
nephropathy progression based on the change in the
fraction of glomerular volume occupied by mesangium
in kidney-biopsy specimens [60].
Reducing albuminuria for renal and cardiovascular
protection
Raised levels of albuminuria are associated with an
increased risk of cardiovascular events. For example,
in the placebo group of the Prevention of Renal and
Vascular Endstage Disease Intervention Trial (PRE-
VEND IT), the incidence of cardiovascular events was
higher if albuminuria was >50 mg/24 hours than if it
was ≤ 50 mg/24 hours [61]. Furthermore, reducing albu-
minuria lowers cardiovascular risk. In the RENAAL trial,
greater reduction in albuminuria in patients with type 2
diabetes conferred greater renal protection [62]. Further
analysis of the RENAAL data, which stratified patients
according to the reduction in albuminuria after 6
months’ treatment (0%, >0-< 30%, and >30%), showed
the incidences of a cardiovascular event and of heart
failure over the 48 months of observation were lowest in
the patients achieving the greatest reduction [63].
Telmisartan in diabetic nephropathy
The efficacy of telmisartan in diabetic patients with
varying degrees of renal dysfunction, ranging from initial
endothelial dysfunction to overt nephropathy, has been
investigated in a total of five studies comprising the Pro-
gramme of Research tO show Telmisartan End-organ
proteCTION (PROTECTION®) [64].
The Telmisartan versus Ramipril in renal ENdothelium
DYsfunction (TRENDY®) study showed that treatment
with telmisartan or ramipril for 9 weeks significantly
improved (p < 0.001) the response of the renal vascula-
ture to nitric oxide, an indicator of basal nitric oxide
activity and thereby of endothelial function of the renal
vasculature [65]. The magnitude of the effect of telmisar-
tan appeared somewhat greater than that of ramipril; this
may explain why only temisartan improved resting renal
plasma flow.
The INcipieNt to Overt: Angiotensin II receptor
blocker, telmisartan, Investigation On type 2 diabetic
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ducted exclusively in Japanese patients with microalbu-
minuria, assessed the transition to overt nephropathy
when treated with telmisartan 40 or 80 mg or with pla-
cebo for up to 2 years [66]. Rates of transition were
16.7% with telmisartan 80 mg, 22.6% with telmisartan
40 mg, and 49.9% with placebo. The renoprotective
effect of telmisartan was similar in the normotensive
patient population and was again dose-dependent.
The Diabetics Exposed to Telmisartan And enalaprIL
(DETAIL®) study compared the effects of the two drugs
on the decline in GFR over 5 years in patients with type
2 diabetes and early nephropathy [67]. The DETAIL®
study used a direct, iohexol-based, measure of GFR -
rather than an indirect estimation from serum creatinine
levels. Both drugs provided similar renal protection.
Comparison between the shorter-term ARB studies,
showed that the annual decline in GFR was lowest with
telmisartan [68], but the cumulative benefit due to the
longer duration of the DETAIL® study cannot be dis-
counted, but it may be that the full renal protective
effect of other ARBs is not achieved within the short-
term follow-up [49,57,69].
A prospective 1-year trial to compare Micardis® ver-
sus losArtan in hypertensive type 2 DiabEtic patients
with Overt nephropathy (AMADEO™) suggests that
renoprotection provided by different ARBs is not the
same when given at doses licensed for the treatment of
hypertension [70]. The patients studied all had urinary
albumin levels >900 mg/24 hours and elevated serum
creatinine (97-265 μmol/L) in women and 115-285
μmol/L in men). When given for 1 year, telmisartan
produced a 29.8% reduction in UACR, whereas that
with losartan was only 21.4% (p = 0.027) (figure 2)
[70]. This represents an approximately 30% difference
in reduction of proteinuria with telmisartan 80 mg ver-
sus losartan 100 mg in favour of telmisartan. The sister
trial, A trial to inVestigate the efficacy of telmIsartan
versus VALsartan in hypertensive type 2 DIabetic
patients with overt nephropathy (VIVALDI®) showed
that telmisartan and valsartan provided equivalent
reductions in proteinuria [71].
Renoprotection in The ONTARGET® Trial Programme
Results from TRANSCEND® assessed the changes in
albuminuria from baseline to after 2 years of treatment
and at the end of the study [4]. The changes in albumi-
nuria were significantly smaller with telmisartan than in
the placebo plus best standard of care group. It should
be noted that these data are based on observations in
the overall patient population of 5,926, approximately
36% of whom had diabetes.
ONTARGET®, the larger of the two studies with in the
trial programme, demonstrated that telmisartan was
more effective than ramipril in slowing down the change
in albuminuria in a population of 25,620 high-risk
patients and that the effect was similar to the one
observed for the combination of ramipril and telmisar-
tan [5]. The difference between treatments was apparent
after 2 years, and differences between telmisartan and
ramipril, and between telmisartan plus ramipril and
ramipril alone, were significant at the end of the 5-year
study (both p < 0.001) (Figure 3) [5]. To date, data on
the renoprotection in the subgroup of 9,612 patients
with diabetes are not available.
Although the combination of telmisartan plus ramipril
provided superior control of albuminuria, the incidence
of the primary renal endpoint for ONTARGET® - a
composite of dialysis (either acute or chronic), doubling
of serum creatinine and death, which is the same as
used in IDNT [49] - was significantly higher for telmi-
sartan plus ramipril versus ramipril alone (HR 1.08 [95%
confidence interval (CI) 1.00, 1.16]) [5]. The most fre-
quent endpoint within the composite was all-cause mor-
tality. If one differentiates between patients who
underwent acute dialysis (i.e. < 2 months’ duration) and
chronic dialysis (an indicator of end-stage renal disease),
the incidence of chronic dialysis was no different in the
telmisartan and the telmisartan plus ramipril groups.
T h e r e f o r e ,t h ed r i v e rf o rt h ed i f f e r e n c ei nt h ep r i m a r y
renal endpoint was acute dialysis, which was twice as
frequent in the combination of telmisartan and ramipril
group compared with the ramipril monotherapy group
(HR 2.19 [95% CI 1.13, 4.22], p = 0.024). Kaplan-Meier
plots for dialysis reveal that the incidence of dialysis
increased in the telmisartan plus ramipril group relative
to the other two groups in the first 2 years of the study;
subsequently, the differences diminished [5].
The decline in estimated GFR in ONTARGET® has
been critically examined. Over 5 years, the loss in esti-
mated GFR was 5.94, 3.96 and 2.66 mL/min in the tel-
misartan plus ramipril, telmisartan and ramipril groups,
Figure 2 Effects of treatment with telmisartan 80 mg or
losartan 100 mg on urinary protein/creatinine ratio (UPCR) in
patients with type 2 diabetes and overt nephropathy (morning
spot UPCR ≥ 700 mg/g creatinine) [70].
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observed in the first 6 weeks of therapy and was greatest
in the patients treated with telmisartan plus ramipril.
High-risk patients with cardiovascular disease are also
likely to have intraglomerular vascular disease, and GFR
is maintained in these patients because of the effect of
angiotensin II. Hence, blockade of the RAS is expected
to generate a short-term loss of GFR. The more effective
the blockade, the greater the loss in GFR, which can
precipitate acute renal failure and the need for short-
term dialysis - which may in turn explain the high need
for acute dialysis in the combination treatment arm.
This decline is likely to be exacerbated if there are chal-
lenges to renal autoregulation by virtue of vascular
pathology - as was likely in the ONTARGET® patient
population. If the annual loss of estimated GFR recorded
in ONTARGET® is comparedw i t ht h o s eo b s e r v e di n
IDNT [49], IRbesartan in patients with type 2 diabetes
a n dM i c r o A l b u m i n u r i a( I R M A - 2 )[ 6 7 ]a n dR E N A A L
[57], the decline in estimated GFR over 5 years was
actually quite acceptable with all three treatments, com-
paring favourably with that observed in a general popu-
lation aged between 65 and 85 years [72].
Of important note is the increase in adverse events in
the combined telmisartan and ramipril arm of the study
with no added benefit [1]. This increased adverse event
rate with ARB + ACE inhibitor with no efficacy benefit
was also seen in the VALsartan In Acute myocardial
iNfarcTion (VALIANT) trial with valsartan and capto-
pril [73]. For this reason, the combination of ARB and
ACE inhibitor is not advised.
Conclusions
An essential component of the management of the dia-
betic patient, especially those with other risk factors such
as nephropathy, is the control of blood pressure to
prevent cardiovascular events and premature death.
Blood pressure targets are in most cases not being met
[74]. A multifactorial approach is needed for the manage-
ment of risk factors (i.e. total cholesterol, hyperglycaemia
and anaemia, as well as blood pressure) in patients with
diabetes. However, management of risk is lamentably
poor - even by diabetologists and nephrologists [75].
Albuminuria provides a simple means of identifying
the onset of kidney and vascular disease and charts the
progression of chronic disease in patients with type 2
diabetes. As well as being a risk factor for ESRD, albu-
minuria is a prognostic factor for cardiovascular mor-
bidity and mortality. Clinical studies in patients with
type 2 diabetes show that the use of ARBs effectively
protects the renal function, the effect being not exclu-
sively attributed to blood pressure control. Post-hoc
analysis of studies evaluating ARBs suggests that this
approach to treatment also reaps cardiovascular benefit.
Telmisartan provides superior reductions of proteinuria,
compared with losartan, and is effective in reducing
renal endpoints. Coupled with evidence of cardiovascu-
l a rp r o t e c t i o ni nO N T A R G E T ® ,t h i sr e i n f o r c e st h e
potential for telmisartan as an alternative to ramipril to
reduce the progression of diabetic nephropathy and to
reduce cardiovascular risk in a high-risk population.
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